Healthcare procurement teams should compare robotic surgical platforms by first defining the institution's highest-volume and highest-priority procedures, then scoring each system against specialty-specific requirements, evidence maturity, training infrastructure, data integration, and total cost of ownership. A structured assessment such as the SAGES Tool for Assessing Robotic Surgery Systems (STARSS) can standardize hardware, safety, and training comparisons, while the IDEAL framework indicates how far a platform has progressed through validation for a given procedure [2][3]. STARSS includes seven categories: General Information, Software Information, Hardware Information, Usability, Safety Features, Ergonomic Capabilities, and Training and Certification [2]. Vendor specifications and economic reviews supply useful inputs, but they require verification against peer institutions and local case mix. A consensus panel of 14 experts with international experience across clinicians, health economists, HTA practitioners, policy makers, and industry identified seven key themes for assessing robotic assisted surgical systems: evidence inclusion and exclusion, patient- and clinician-reported outcomes, the learning curve, allocation of costs, appropriate time horizons, economic analysis methods, and robotic ecosystem/wider benefits [7]. The comparison should not seek a universal winner; a platform that fits an academic teaching hospital may be poorly matched to a community hospital's narrower procedural range and capital constraints [1]. The panel describes robotic surgical platforms as tools whose value depends on context and stakeholder needs. Its funding disclosure states that Alira Health received consulting fees from Intuitive Surgical to coordinate the meetings and that panel members received travel and accommodation reimbursement. That commercial connection is a limitation to consider when using the consensus statements in a purchasing comparison [7]. Procurement decisions become defensible when each criterion is tied to documented evidence and an explicit institutional priority.
Start with procedural fit and institutional setting
The first decision point is not the robot's brand but the procedures it must support. A white paper on preacquisition evaluation notes that general surgery requires exceptional procedural diversity, ranging from cholecystectomies to complex hepatobiliary resections, while urology and other specialties impose different priority criteria [1]. Institutions should evaluate platforms based on their highest-volume and highest-priority procedures because platform capabilities vary significantly across surgical applications [1]. A community hospital with a concentrated case mix may therefore weigh different features than an academic center that needs dual-console operation for education and advanced systems for complex procedures [1].
Academic centers face distinct economic pressure from payer mix and case complexity, requiring higher case volumes for financial sustainability [1]. This means the same capital purchase can produce different operating economics in different settings. Procurement teams should document the expected annual case volume by specialty before soliciting vendor proposals. Without that baseline, comparisons of instrument cost, docking time, or console configuration cannot be translated into local financial impact. The setting also shapes credentialing requirements; specialized credentialing pathways must exceed minimum standards to ensure trainee proficiency without compromising patient safety [1]. Academic centers typically require dual-console operation for education, comprehensive data collection for performance improvement initiatives, and advanced systems for complex procedures [1].

Use structured tools to compare hardware and workflow
STARSS offers a reproducible way to compare FDA-cleared robotic systems across general information, hardware, integration, safety, and training categories [2]. The tool records device name, manufacturer, indications, certification, market status, and system cost, while acknowledging that prices may change with time and installation differences and can vary for the same system by geographic location [2]. Hardware metrics include patient cart and vision cart quantity, system size in cubic feet, open or closed surgeon console, and sit/stand capability [2]. Integration is rated as limited, medium, or good, alongside whether the platform requires laparoscopic equipment for preparation and how well the team can use verbal and non-verbal communication during surgery [2].
Camera control mechanisms also affect workflow and learning curves. Eye-tracking, hand controls, and voice-activated systems differ across platforms and specialties [1]. The STARSS tool also rates integration of equipment with operating room equipment as limited, medium, or good, and records whether each platform requires laparoscopic equipment to prepare for use [2]. Procurement teams can use STARSS to normalize these differences rather than relying on vendor demonstrations. The tool's training section measures procedures to proficiency for a specific surgical task, dexterity enhancement compared with laparoscopy, availability of a skills curriculum, training for the entire OR team, performance assessment tools, feedback, and training support [2]. These metrics matter because early inefficiencies can increase non-surgical operative time until team proficiency improves [5]. The STARSS training category also measures dexterity enhancement compared with laparoscopy, availability of a skills curriculum, training for the entire OR team, performance assessment tools, feedback, and training support [2].
A suggested evaluation workflow for a mid-sized hospital
A procurement team could begin by listing the top five procedures by annual volume and assigning each a priority weight. For a hospital planning 200 robotic prostatectomies and 150 hysterectomies per year, the team would request procedure-specific IDEAL stage evidence for each candidate platform [1][3]. The team would also document expected annual case volume by specialty before soliciting vendor proposals, since the same capital purchase can produce different operating economics in different settings [1]. The team would then complete STARSS for each shortlisted system, scoring hardware, integration, safety, and training metrics [2]. Vendor-reported costs would be normalized using local instrument usage and expected non-surgical operating time, with early inefficiency assumptions drawn from published economic reviews [5]. Finally, the team would interview existing customers about clinical specialist availability and technical service response times [1]. The team should also verify whether the platform can export structured procedural data into the hospital's EMR and analytics environment, since platforms vary significantly in capturing procedural data, integrating with institutional data warehouses, and supporting interoperability [1]. This workflow is a suggestion, not a tested protocol, and each step should be adapted to local governance and data availability. The IDEAL Robotics Colloquium recommends early and iterative economic modeling, using exploratory analyses to guide cost-effective development, and comprehensive robotic surgery registries or systems for extracting reliable information from existing real-world data sources [3].
Assess evidence maturity with the IDEAL framework
Evidence maturity should be evaluated separately for each procedure, not for the platform as a whole. Established systems such as da Vinci have reached IDEAL Stages 3 to 4 for procedures like prostatectomy and hysterectomy, while newer platforms currently lie in Stages 1 to 2 [1]. A scoping review identified 21 companies with 23 different robotic platforms; of the 17 multiport systems, 1 was fully evaluated at stage 4, 2 were stage 3, 6 stage 2b, 2 stage 2a, 2 stage 1, and 4 at the pre-IDEAL stage 0, while none of the 6 single-port systems had been fully evaluated [6]. This distinction matters because a platform may have mature evidence for one indication and limited evidence for another. Procurement teams should request procedure-specific evidence rather than accepting aggregate clinical claims.
The IDEAL Robotics Colloquium recommends early and iterative economic modeling, using exploratory analyses to guide cost-effective development [3]. It also calls for comprehensive robotic surgery registries and real-world data sources that can inform consent and long-term monitoring [3]. The colloquium further recommends that current data should inform the consenting process and that evidence referred to when seeking informed consent must relate to the indication and not simply to the device [3]. For procurement, this means asking vendors which IDEAL stage their system has reached for the institution's target procedures and what registry or real-world data exist. The IDEAL Robotics Colloquium also recommends that public and patient involvement should inform the design of IDEAL stage 4 studies and outcome measures where mechanisms to support this exist [3]. A platform with only Stage 1 or 2 evidence may still be appropriate for a controlled adoption program, but the decision should acknowledge that long-term safety and effectiveness data are not yet available [6]. The IDEAL Robotics Colloquium also notes that evidence referred to when seeking informed consent must relate to the indication and not simply to the device, since robotic systems may be used for many different procedures [3].
Compare total cost of ownership and support services
Economic comparisons should include acquisition, maintenance, instruments, and non-surgical operating time. A review of next-generation systems found that Hugo RAS and KangDuo showed lower total procedural expenses in some series, although early inefficiencies may increase initial non-surgical operative time until team proficiency improved [5]. The da Vinci Single Port platform demonstrated possible cost increases relative to the multiport system, largely influenced by institutional discharge pathways and disposable pricing [5]. These findings are heterogeneous and procedure-specific; radical prostatectomy was the most frequently evaluated procedure, with additional analyses focused on colorectal surgery, hysterectomy, sacrocolpopexy, total mesorectal excision, and pyeloplasty [5]. Economic outcomes varied markedly across institutions, driven by local procurement policies, instrument pricing, operative workflows, and reimbursement models [5].
Support services directly affect program sustainability. Clinical specialist availability and expertise vary considerably between vendors, affecting in-room support during initial implementation and complex cases [1]. Intuitive reports dual-console training, structured training pathways across surgeons, care teams, and reprocessing staff, and more than 101,000 surgeons trained globally [4]. Technical service response times and resolution rates should be verified through discussions with existing customers rather than relying solely on contractual guarantees [1]. Intuitive states that it supports approximately 2.3 million procedures globally per year through supply continuity and stability, and that its Genesis OR efficiency program has a dedicated support team [4]. Intuitive also reports that more than 99% of procedures are completed and more than 99% of tech support calls are answered within 25 seconds, with 24/7 technical support and real-time remote access to the system [4]. These are vendor-reported figures and should be checked against peer accounts and local service history.
Evaluate data integration, interoperability, and future flexibility
Platforms vary significantly in capturing procedural data, integrating with institutional data warehouses, and supporting interoperability [1]. These capabilities become more important as surgical data gain value for performance improvement and research [1]. Procurement teams should ask whether the system can export structured procedural data into the hospital's EMR and analytics environment. Intuitive describes custom hospital analytics, called MACA, that provide a combined view of clinical, financial, and operational performance using EMR and administrative data [4]. This is a vendor description and should be tested against the institution's actual data architecture.
The trend toward procedure-specific systems is accelerating. Emerging miniaturized platforms, such as Johnson & Johnson's Monarch Platform for bronchoscopic procedures and the MIRA miniature robot, suggest diversified robotic technologies [1]. The FDA's draft guidance on robotically-assisted surgical devices notes that pre-operative planning systems and stereotaxic systems are not RASDs and are outside its scope [8]. Institutions should evaluate whether current investments position them to adopt specialized systems as complements to general-purpose platforms and assess integration potential [1]. A procurement decision that locks the hospital into a closed ecosystem may limit future adoption of procedure-specific devices. Contract flexibility and data portability should therefore be scored alongside clinical features.
Sources & references
- White paper on effective preacquisition evaluation of soft tissue robotic surgery platforms for healthcare institutions | Surgical Endoscopy | Springer Nature Link · link.springer.com
- SAGES tool for assessing robotic surgery systems (STARSS) | Surgical Endoscopy | Springer Nature Link · link.springer.com
- The IDEAL framework for surgical robotics: development, comparative evaluation and long-term monitoring | Nature Medicine · www.nature.com
- Intuitive Ecosystem | Information for Purchases · www.intuitive.com
- Economic assessment of next-generation robotic surgical systems compared with the multiport da Vinci platform: a comprehensive review | Journal of Robotic Surgery | Springer Nature Link · link.springer.com
- Evaluation status of current and emerging minimally invasive robotic surgical platforms | Surgical Endoscopy | Springer Nature Link · link.springer.com
- Best practice considerations on the assessment of robotic assisted surgical systems: results from an international consensus expert panel | International Journal of Technology Assessment in Health Care | Cambridge Core · www.cambridge.org
- Robotically-Assisted Surgical Devices - Premarket Submissions · www.fda.gov
